Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Summary

The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications